The Technical Analyst
Cibus, Inc. [CBUS]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Cibus, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-3.51% $17.06
/ 7 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 422.50 mill |
| EPS: | -25.95 |
| P/E: | -0.660 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 24.77 mill |
| Avg Daily Volume: | 0.0672 mill |
| RATING 2024-05-07 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.660 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.660 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-2.44 (-114.33%) $-19.50 |
| Date: 2024-05-07 |
| Expected Trading Range (DAY) |
|---|
|
$ 15.64 - 18.48 ( +/- 8.31%) |
| ATR Model: 14 days |
Forecast:
16:00 - $16.95
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $16.95
Forecast 2: 16:00 - $16.95
Forecast 3: 16:00 - $16.95
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $17.06 (-3.51% ) |
| Volume | 0.0609 mill |
| Avg. Vol. | 0.0672 mill |
| % of Avg. Vol | 90.64 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CBUS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:29 | buy | $18.64 | N/A | Active |
|---|
CBUS
Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.
Latest Press Releases
2024-04-25 07:00:00 - Press Release
Cibus To Report First Quarter 2024 Financial Results On May 9, 2024 And Host Conference Call
San diego, april 25, 2024 (globe newswire) -- cibus, inc. (nasdaq: cbus), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2024 financial results on thursday, may 9, 2024. cibus' management team will host a conference call and audio webcast at 4:30 p.m. et on that day to discuss the financial results and other company updates.
2024-03-21 16:05:00 - Press Release
Cibus Reports Fourth Quarter Financial Results And Provides Business Update
Completed successful transfers of gene edited elite germplasm back to customers for commercialization for each of its three developed productivity traits: pod shatter reduction (psr) in canola and herbicide tolerance (ht1 and ht3) in rice
2024-03-13 07:35:00 - Press Release
Cibus To Participate In The 36th Annual Roth Conference
San diego, march 13, 2024 (globe newswire) -- cibus, inc. (nasdaq: cbus), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that rory riggs, co-founder, chief executive officer, and chairman, and peter beetham, co-founder, president, and chief operating officer will participate in a panel at the 36th annual roth conference taking place march 17-19, 2024.
2024-02-26 07:00:00 - Press Release
Cibus And Loveland Products Collaborate To Develop And Sell Rice Traits In The Us
San diego, feb. 26, 2024 (globe newswire) -- cibus, inc. (nasdaq: cbus), a leading agricultural technology company that develops and licenses non-gmo plant traits to seed companies, today announced that it has entered into a us development agreement with loveland products inc., a subsidiary of nutrien ltd. (tsx and nyse: ntr). cibus has agreed to collaborate with loveland products to provide traits into loveland's elite rice seed genetics.
2024-01-17 07:00:00 - Press Release
Cibus 2023 Field Trial Results Move Developed Traits Closer To Product Sales
San diego, jan. 17, 2024 (globe newswire) -- cibus, inc. (nasdaq: cbus), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company is moving forward in the next step of commercialization of its developed traits.
Latest News
2024-04-25 07:00:00 - GlobeNewsWire
Cibus to Report First Quarter 2024 Financial Results on May 9, 2024 and Host Conference Call
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2024 financial results on Thursday, May 9, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.
2024-03-25 16:21:15 - Zacks Investment Research
Cibus (CBUS) Reports Q4 Loss, Tops Revenue Estimates (Revised)
Cibus (CBUS) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $3 per share a year ago.
2024-03-21 19:51:03 - Zacks Investment Research
Cibus (CBUS) Reports Q4 Loss, Tops Revenue Estimates
Cibus (CBUS) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $3 per share a year ago.
2024-03-21 19:39:10 - Seeking Alpha
Cibus, Inc. (CBUS) Q4 2023 Earnings Call Transcript
2024-03-18 09:30:30 - Zacks Investment Research
Cibus (CBUS) Moves 6.7% Higher: Will This Strength Last?
Cibus (CBUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2024-02-24 03:04:59 - Seeking Alpha
EU Greenlights Cibus To Enter Its Massive Market
Cibus is a pioneer in the use of gene editing in agriculture, a non-GMO technology that will likely drive the next agricultural revolution. Regulation is a gating market factor for any new crop variety as GMO crops are banned in many markets, and are subject to lengthy regulatory review where permitted. On Feb. 7, the European Parliament approved new regulations that treat gene-edited crops as conventional plant breeding rather than GMO.
2024-01-12 17:10:31 - Seeking Alpha
Cibus: Expanding Opportunities And Growing Accessible Market
Cibus, a gene editing pioneer in agriculture, has announced collaborations that could significantly increase its revenues. The company has partnered with Interoc to breed rice hybrids with herbicide tolerance for the Latin American market. Further deals in Latin America could double or triple accessible rice acreage. Cibus has also achieved a breakthrough in regenerating wheat plants from single cells, opening up a large addressable market for enhanced forms of wheat.
2023-11-11 21:19:03 - Seeking Alpha
Cibus, Inc. (CBUS) Q3 2023 Earnings Call Transcript
Cibus, Inc. (NASDAQ:CBUS ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Wade King - Chief Financial Officer Rory Riggs - Co-Founder, Chief Executive Officer and Chairman Peter Beetham - Co-Founder, President and Chief Operating Officer Conference Call Participants Bobby Burleson - Canaccord Genuity Kevin Estok - Jefferies Operator Good afternoon, and welcome to the Cibus Third Quarter 2023 Results Conference Call. [Operator Instructions] Please also note, today's event is being recorded.
2023-10-27 10:55:57 - Seeking Alpha
Cibus: A Pioneer In Gene Editing, The Future Of Agriculture
Gene editing, a non-GMO technology, has the potential to revolutionize agriculture by increasing crop yields, making plants more resilient, and meeting the challenges of climate change. Cibus, a company specializing in gene editing, partners with agricultural giants to develop crops with desirable traits. The company's gene editing technology is protected by roughly 400 issued patents, giving it a significant advantage over competitors.
2023-10-03 08:05:00 - Seeking Alpha
5 REITs That Are Overleveraged
Most REITs have strong balance sheets. But there are exceptions that are heavily overleveraged. I highlight 5 REITs that are risky.